A5014264319- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Pediatric health and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Urticaria and Related Conditions
- Food Allergy and Anaphylaxis Research
- Dermatology and Skin Diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Olfactory and Sensory Function Studies
- Cancer Research and Treatments
- Human Health and Disease
- Eosinophilic Esophagitis
- IL-33, ST2, and ILC Pathways
- Healthcare Systems and Public Health
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Electron and X-Ray Spectroscopy Techniques
- Advanced Materials Characterization Techniques
- Advancements in Photolithography Techniques
- Genomics and Phylogenetic Studies
- Nasal Surgery and Airway Studies
- Mast cells and histamine
- SARS-CoV-2 and COVID-19 Research
- Synthesis and Characterization of Heterocyclic Compounds
- Machine Learning in Bioinformatics
Russian Medical Academy of Continuous Professional Education
2016-2025
Ministry of Health of the Russian Federation
2016-2024
Universität Greifswald
2023-2024
Institute of Mathematics and Computer Science
2023
Ministry of Health
2019-2021
European Respiratory Society
2015
Russian Respiratory Society
2015
The Earth Biogenome Project has rapidly increased the number of available eukaryotic genomes, but most released genomes continue to lack annotation protein-coding genes. In addition, no transcriptome data is for some genomes.
The article provides a review on prevalence, phenotypes, endotypes, and the control of severe bronchial asthma. Severe asthma is widespread, heterogeneous disease that affects 5 – 20% patients with Prevalence in Russia significantly exceeds official statistics data, therefore it necessary to maintain national register conventional therapy for not always effective due uncontrolled course eosinophilic airway inflammation. identification phenotype/endotype reasonable develop personalized...
Bronchial asthma is a heterogeneous disease that requires identification of its phenotype and personalized approach to therapy. At the same time, despite wide range therapeutic options, many patients with cannot achieve control over disease. Methodology . The target audience these clinical recommendations are general practitioners, therapists, pediatricians, allergologists-immunologists, pulmonologists, functional diagnostics doctors. Each thesis-recommendation about diagnostic procedures...
The Expert Council was devoted to the development of algorithm diagnostics and treatment anxiety disturbances in patients with somatic diseases general clinical practice. level clinicians from various medical fields took part creation algorithm, which allowed take into account different approaches opinions. is aimed at identifying a profile their timely treatment. Temgicoluril discussed as one recommended drugs for conditions outpatient
BackgroundThe 2021 Global Initiative for Asthma (GINA) report recommends 2 treatment tracks depending on choice of reliever therapy: either inhaled corticosteroid (ICS)/formoterol, or short-acting β2-agonist (SABA) with ICS to be used whenever a SABA is taken.ObjectiveThe Patients' and Physicians' Perspectives the Burden Management (APPaRENT) study aimed understand current real-world approaches their alignment GINA recommendations.MethodsPatients physicians were recruited online survey from...
Introduction Treatment with biologics for severe asthma is informed by international and national guidelines defined regulating bodies, but how these drugs are used in real-life unknown. Materials methods The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on use Europe. Five geographically distant countries the questions, focusing seven end-points: availability financial issues, prescription administration...
Bronchial asthma is a heterogeneous disease with variable course. Identification of pathobiological mechanisms phenotype, also called as endotypes, an urgent task to optimize treatment asthma, especially severe asthma. Although the author recognizes that T2-low serious problem, this article devoted T2-high endotype. Currently, biological agents are available for only, so focus on T2 high important. Current characteristics uncontrolled, difficult-to-treat and eosinophilic inflammation in main...
Atopic dermatitis is one of the most common diseases (20‒40% among skin diseases) that occur in both genders worldwide and different age groups. The problem urgency caused by an increase morbidity, a chronic relapsing course often leads to decrease quality life disability, low efficiency traditional treatment methods, limited access contemporary effective targeted therapy. clinical guidelines, which aimed optimize care for patients with atopic dermatitis, contain up-to-date information on...
Biological therapy of bronchial asthma (BA) is a modern method treating severe forms the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations registered in world for treatment (SBA) T2 endotype (T2-SBA) – antibodies, binding to immunoglobulin (Ig) E (anti-IgE omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 mepolizumab, resizumab) and its receptor (anti-IL-5Rα benralizumab), as well selectively bind IL-4 -13...
<b><i>Introduction:</i></b> Allergic rhinitis (AR) is a disease that affects ≤24% of people in Russia, significantly impairing quality life (QoL). Intranasal corticosteroids, such as triamcinolone acetonide (TAA), are considered effective drugs for treatment. A post hoc analysis data (phase III NASANIF trial) examined weekly QoL changes patients receiving TAA the treatment perennial AR (PAR). <b><i>Methods:</i></b> (NCT03317015) was...
Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking severe asthma patients in Europe reorganised care, and these changes affected patient satisfaction, control future care. Methods In this European-wide cross-sectional study, surveys were sent to with a physician-diagnosis asthma, physician specialists between November 2020 May 2021. Results 1101 268...
Aim. Effectiveness and safety of levosalbutamol metered dose inhaler (MDI) in comparison with placebo salbutamol. Materials methods. In this multicenter, randomized, placebo-controlled, 3-period crossover study, all asthma patients (n=91) received (90 mcg), salbutamol (180 using standard MDI. Pulmonary function testing – forced expiratory volume the first second (FEV1) vital capacity (FVC) was performed 45 15 minutes before 5, 10, 15, 30, 60, 90, 120, 180, 240, 300 360 after dosing. The...
Asthma and chronic obstructive pulmonary disease remain major problems of medicine, still there is need to improve the level quality diagnosis these diseases. Primary care physicians (general practitioners, therapists) should be involved widely actively in this process. To simplify diagnosis, special questionnaires have been developed, they can used a real clinical practice. Only approach will bring statistical data closer true prevalence diseases their treatment.
Aim. Creation of the "Russian register patients with severe asthma" and obtaining data on population characteristics asthma (SA), prevalence SA phenotypes, treatment outcomes degree disease control. Materials methods. Observational non-interventional study, which consists in analysis obtained basis registration cards Russian Register Patients Severe Bronchial Asthma, collection was carried out Oracle XE platform. Statistical processing using Power BI, PSPP Microsoft Excel spreadsheets....
The current state of the patients’ management with nasal polyposis and allergic rhinitis has become basis for a deep analysis currently available data on prevalence diseases (with focus severe forms), as well, possibilities disadvantages conservative therapy are considered. approaches to assessing severity control influence an uncontrolled course quality life presented. Particular attention is paid new class drugs – monoclonal antibodies, which might change treatment paradigm polyposis....
There are results of a comparative phase III clinical study on the efficiency and safety biosimilar drug Genolar® (Generium JSC, Russia) reference Xolair® (Novartis Pharma AG, Switzerland) ((NCT04607629). The is aimed to establish equivalence compared drugs for additional therapy patients with moderate severe bronchial asthma (BA) considered in article. Methods. enrolled 191 aged 18 75 years atopic ≥ 1 year, symptoms which were insufficiently controlled by corresponding 4 th stage treatment...
Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half patients. In recent years, there have been significant changes the approaches to treatment bronchial and, above all, eosinophilic asthma. The article discusses role eosinophils pathogenesis detection and modern targeting with an using biological agents. A special emphasis placed on preparations monoclonal antibodies interleukin-5, particular, mepolizumab, recently approved for clinical use our country.
Recently, bronchial asthma is considered as a heterogeneous disease characterized by chronic airway inflammation and respiratory symptoms, which vary in time intensity manifest together with variable obstruction of the airways. Asthma one most common diseases primary care. Patients certain symptoms seek for medical aid initially care physicians, such therapeutists, general practitioners, family who can suspect diagnose asthma, obstructive pulmonary (COPD), allergic rhinitis, etc. Currently,...
Relevant indications for tiotropium Respimat in adult patients with bronchial asthma (BA) were reviewed. This consensus represents a collaborative effort of members the Executive Group Russian Respiratory Society. The consisted clinicians, pharmacologists and researchers recognized expertise therapeutic field. draft recommendations was prepared by initiative group. Each point recommendation discussed during group meeting accepted vote majority members. Final version statement approved each...